Exploring immunotherapy options for adrenocortical carcinoma
Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
This study is testing new immunotherapy treatments for people with adrenocortical carcinoma to see if they can help improve outcomes for this rare and aggressive cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wuerzburg Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Wuerzburg) |
| Trial ID | NCT00457587 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on adrenocortical carcinoma (ACC), a rare cancer with a high recurrence rate after surgical treatment. It aims to establish a foundation for developing immunotherapy as a new treatment option for patients with ACC. The study includes patients with histologically confirmed ACC and healthy individuals as a control group, assessing the potential of immunotherapy in this context. The research is crucial due to the urgent need for effective treatments for this aggressive malignancy.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically proven adrenocortical carcinoma and healthy individuals for comparison.
Not a fit: Patients with autoimmune diseases or severe clinical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new immunotherapy options that improve outcomes for patients with adrenocortical carcinoma.
How similar studies have performed: While there is ongoing research in immunotherapy for various cancers, this specific approach for adrenocortical carcinoma is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with histological proven adrenocortical carcinoma * healthy persons as control group * Life expectancy \> 6 months Exclusion Criteria: * autoimmune diseases * severe clinical condition
Where this trial is running
Wuerzburg
- Dept. of Medicine I, University of Wuerzburg — Wuerzburg, Germany (Recruiting)
Study contacts
- Principal investigator: Martin Fassnacht, MD — University of Wuerzburg
- Study coordinator: Martin Fassnacht, MD
- Email: fassnacht_m@medizin.uni-wuerzburg.de
- Phone: 49-931-201-36507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.